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Abstract. Ovarian cancer is the most lethal gynecological
cancer among women worldwide. Adverse side effects and
acquired resistance to conventional platinum based chemotherapy are major impediments in ovarian cancer treatment,
and drive the development of more selective anticancer drugs
that target cancer-specific defects. In this study, theaflavin-3,
3'-digallate (TF3), the major theaflavin monomer in black tea,
exhibited a potent growth inhibitory effect on the cisplatinresistant ovarian cancer A2780/CP70 cells (IC50, 23.81 µM),
and was less cytotoxic to a normal ovarian IOSE‑364 cells
(IC50, 59.58 µM) than to the cancer cells. Flow cytometry
analysis indicated that TF3 induced preferential apoptosis
and G2 cell cycle arrest in A2780/CP70 cells with respect
to IOSE‑364 cells. TF3 induced apoptosis through both the
intrinsic and extrinsic apoptotic pathways, and caused G2
cell cycle arrest via cyclin B1 in A2780/CP70 cells. The p53
protein played an important role in TF3-induced apoptosis and
G2 cell cycle arrest. TF3 might upregulate the p53 expression
via the Akt/MDM2 pathway. Our findings help elucidate the
mechanisms by which TF3 may contribute to the prevention
and treatment of platinum-resistant ovarian cancer.
Introduction
Ovarian cancer is the second most common and the most lethal
of malignancies arising in the female reproductive system (1).
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Response rates to first-line platinum-based therapy are >80%,
but the overall 5-year survival rate for patients with advanced
ovarian cancer is only ~20% because of acquired drug
resistance and adverse side effects. Therefore, overcoming
drug resistance is the key to successful treatment of ovarian
cancer, and the development of novel therapeutic approaches
is urgently needed (2).
Apoptosis is an active death process genetically encoded
that can be triggered by a wide variety of extra- and intracellular stimuli. Recent evidence suggests that the failure
of drug-induced apoptosis may be an underlying cause of
drug resistance. Molecular mechanisms of failed apoptosis
in chemoresistant ovarian cancer cells include p53 mutations, abnormal expression of the Bcl-2 family proteins and
P-glycoproteins, and upregulation of other inhibitors of
apoptosis that block caspases and stabilize the mitochondrial
permeability pore. Triggering apoptosis is one of the potential
strategies to overcome chemoresistance (3,4). The cell cycle is
a series of events that take place in a cell leading to its division
and duplication that produces two daughter cells. This process
involves four sequential phases that go from quiescence
(G0 phase) to proliferation (G1, S, G2, and M phases) and back
to quiescence. A disregulation of the cell cycle components
may lead to tumor formation. A number of potential molecular
targets for novel anticancer drug discovery have been identified in cell cycle control mechanisms (5,6).
It is a common belief that compounds from fruits,
vegetables and other foods will help reduce the risk of various
chronic diseases including cancer, and have less side effects
(7). Black tea is the most widely consumed beverage worldwide, and accounted for ~80% of the dried tea manufactured
annually (8). It was reported that black tea extract possess
potently antiproliferative property against a variety of cancer
cells in vitro and in vivo (9,10). In particular, the previous
prospective cohort study showed that black tea was a main
dietary source of flavonols for US women, and its intake was
associated with lower risk of ovarian cancer (11).
Theaflavins are major bioactive components in black tea,
and contribute importantly to properties of black tea including
its color, ‘mouth feel’ and extent of tea cream formation.
They possess a benzotropolone skeleton that is formed from
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co-oxidation of appropriate pairs of catechins during the
production of black tea (12). The major theaflavins in black tea
are theaflavin (TF1), theaflavin-3-gallate (TF2A), theaflavin3'-gallate (TF2B) and theaflavin-3, 3'-digallate (TF3), and TF3
(Fig. 1) is usually most abundant among them (13). Theaflavins
have been demonstrated to inhibit proliferation and induce
apoptosis in a variety of cancer cells including human breast
cancer MCF-7 cells, malignant melanoma A375 cells and oral
squamous carcinoma HSC-2 cells. In addition, theaflavins are
responsible for the inhibition of ROS-potentiated AH109A
adhesion and invasion to the cultured rat mesothelial cell
monolayer (14-17).
Although theaflavins have received considerable attention
for their anticancer activity, their effect on the ovarian cancer
is still not clear. Therefore, the aim of this study was to investigate the apoptotic and cell cycle arrest effects of TF3 in the
platinum-resistant ovarian cancer cell line A2780/CP70 and
a normal ovarian surface epithelial cell line IOSE‑364. The
possible mechanisms underlying these modulations of TF3 on
the ovarian cancer cells were also examined.
Materials and methods
Cell culture and reagents. The platinum-resistant human
ovarian cancer cell line A2780/CP70 (p53 wild-type) was a
generous gift from Dr Β. Jiang at West Virginia University.
IOSE‑364, a normal ovarian surface epithelial cell line,
was presented by Dr Ν. Auersperg at University of British
Columbia, Canada. The cells were cultured in RPMI-1640
medium (Sigma) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen) at 37˚C in a humidified incubator
with 5% CO2. Theaflavin-3, 3'-digallate (TF3, >90.0%) was
purchased from Sigma-Aldrich (St. Louis, MO, USA). The
primary antibodies against Bcl-xL, Bad, p21, p53, MDM2
and GAPDH were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). The primary antibodies against
caspase-8 and -9, Puma, Bax, cyclin B1, phospho-cdc2 (Tyr15),
cdc2, DR5, FADD, phospho-Akt (Thr180/Tyr182) and totalAkt were purchased from Cell Signaling Technology, Inc.
(Danvers, MA, USA).
Cell viability assay. The cell viability was assessed a using
3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay. Briefly, the cells (1x104 cells per well)
were seeded in 96-well plate and incubated overnight. Then
various concentrations of TF3 (0-50 µM) were added, and an
equal amount of DMSO was used as control. After treatment
for 24 h, 20 µl of MTT (5 mg/ml) was added to each well
and incubated for an additional 4 h at 37˚C in the dark. The
medium was discarded, and the formazan crystals formed in
the cells were dissolved in 200 µl DMSO. The optical density
was measured at 570 nm using a Synergy™ HT Multi-Mode
Microplate Reader (BioTek).
Flow cytometric analysis of apoptotic cells. The apoptotic cell
death was determined using an Alexa Fluor® 488 Annexin V/
Dead Cell Apoptosis kit (Invitrogen). After exposure to TF3
(0-20 µM) for 24 h, cells were harvested, centrifuged for
10 min at 1500 rpm and then washed twice with PBS. Cells
were suspended in binding buffer with Alexa Fluor 488

Annexin V and propidium iodide (PI) for 15 min. The stained
cells were analyzed by flow cytometry (FACSCalibur system,
BD Biosciences), measuring the fluorescence emission at 530
and 575 nm using 488 nm excitation.
Flow cytometry analysis of the cell cycle. Cells treated with
TF3 (0-20 µM) for 24 h were digested with trypsin and
harvested by 1500 rpm centrifugation for 10 min. The cell
pellet was suspended with 70% ethanol at -20˚C overnight,
washed with PBS, then incubated with 180 µg/ml RNase A at
37˚C for 15 min. After 15 min staining with 50 µg/ml PI in the
dark at 37˚C, the samples were analyzed by flow cytometry
(FACSCalibur system, BD Biosciences). Data were plotted
and analyzed by using FCS Software (De Novo Software, Los
Angeles, CA, USA).
Caspase-3/7 assay. The caspase-3/7 activities in A2780/CP70
and IOSE‑364 cells were detected using a Caspase-Glo 3/7
Assay kit (Promega). Cells were seeded in 96-well plates at
1x104 cells/well, incubated overnight, and treated with TF3
(0-20 µM) for 24 h. After treatment, 100 ml of caspase-3/7
reagent were added to each well, mixed and incubated for
1 h at room temperature. Luminescence was measured using
a Synergy™ HT Multi-Mode Microplate Reader (BioTek).
Caspase-3/7 activities were normalized by total protein levels,
and were expressed as percentage of the untreated control.
The total protein levels were measured with a BCA assay kit
(Pierce).
Western blotting. A2780/CP70 ovarian cancer cells were
seeded in 60-mm dishes at 1x106 cells/dish, incubated overnight, and treated with 0-20 µM TF3 for 24 h. Then cells were
harvested with M-PER Mammalian Protein Extraction Reagent
(Pierce) supplemented with Halt Protease and Phosphatase
Inhibitor (Pierce), and total protein levels were assayed with
BCA Protein assay kit (Pierce). Cell lysates were separated by
SDS-PAGE and blotted onto nitrocellulose membrane with a
Mini-Protean 3 System (Bio-Rad). The membrane was blocked
with 5% skim milk, and then incubated with specific primary
antibodies and appropriate secondary antibodies conjugated
with horseradish peroxidase. The antigen-antibody complex
was visualized with the ECL kit (Pierce). Protein bands were
quantitated with NIH Image J software and normalized by
GAPDH bands for analysis.
Transfection with small interfering RNA (siRNA). A2780/
CP70 ovarian cancer cells were seeded in 60-mm dishes at
5x105 cells/dish, incubated overnight, and then transfected
with p53 siRNA (Santa Cruz) using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's
protocol. Cells transfected with control siRNA (Santa Cruz)
were used as controls. After a 24-h transfection period, cells
were treated with TF3 (0-20 µM) for 24 h. Cell lysates were
collected for western blot analysis.
Statistical analysis. In this study, all samples were prepared
and analyzed in triplicate. The data are presented as means
± standard deviations (SD). Multiple comparisons were
performed by one-way analysis of variance (ANOVA)
followed with Student-Newman-Keuls (SNK) test. Statistical
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Figure 2. Effect of TF3 on cell growth in human ovarian cancer cells A2780/
CP70 and normal ovarian cells IOSE‑364. Cells (1x104/well) were seeded in
96-well plates, incubated overnight, and then treated with TF3 for 24 h. Cell
viability was determined by MTT assay. Data represent means ± SD from
three independent experiments. Significant differences among the treatments
are indicated by different letters (p<0.05).

Figure 1. Chemical structure of TF3 used in this study.

differences between two groups were evaluated using the
Student's t-test. All statistical analyses of data were performed
using Statistical Analysis System (SAS) for windows V8. A
p<0.05 was considered statistically significant, and p<0.01
was considered statistically highly significant.

Table I. Cell cycle phase distribution of A2780/CP70 and
IOSE‑364 cells with TF3 treatment.
Cell cycle phase distribution
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Cell lines
TF3
% G1
% G2
%S
(µM)
A2780/CP70

Results
Effect of TF3 on A2780/CP70 and IOSE‑364 cell viability.
The cytotoxicity of TF3 on A2780/CP70 and IOSE‑364 cells
was analyzed using the MTT assay. As shown in Fig. 2, TF3
inhibited the growth of both the cell types in a dose-dependent
manner. The cell viability with TF3 treatment (0-50 µM) for
24 h ranged from 100 to 11.38% for A2780/CP70 cells, and
from 100 to 58.14% for IOSE‑364 cells. The IC50 values of
TF3 for A2780/CP70 and IOSE‑364 cells were estimated to
be 23.81 and 59.58 µM, respectively. These results indicated
that TF3 had lower cytotoxic effect against normal ovarian
IOSE‑364 cells than ovarian cancer A2780/CP70 cells.
TF3 induces apoptosis in A2780/CP70 cells. To investigate
whether TF3 inhibited cell viability by inducing apoptosis in
A2780/CP70 and IOSE‑364 cells, the cells were treated with
TF3 (0-20 µM) for 24 h and subsequently subjected to double
staining with Annexin V FITC and propidium iodide (PI)
followed by flow cytometry analysis. As shown in Fig. 3A,
the treatment of TF3 increased the total percent of apoptotic
cells (upper right quadrant + low right quadrant) from 3.28
to 22.47% in A2780/CP70 cells, but could hardly induce
apoptosis of IOSE‑364 cells in the test range of 0-20 µM.
To confirm that TF3 induced apoptosis, caspase-3/7 enzymatic activities were evaluated in both cell lines. As shown

IOSE‑364

0
5
10
20
0
5
10
20

42.47±1.33a
39.32±2.71a
26.57±1.26b
21.81±1.94c
32.93±0.85a
31.52±2.23a
29.55±2.71a
30.32±1.64a

18.00±1.22d
25.04±0.79c
29.08±0.86b
39.78±1.73a
32.91±1.47b
35.35±2.39b
39.08±1.24a
39.59±1.67a

39.53±2.65a,b
35.64±1.87b
44.35±3.37a
38.41±2.83a,b
34.16±1.93a
33.14±2.61a
31.37±1.06a
30.08±2.27a

Data represent means ± SD from three independent experiments.
Values in a column followed by different letters are significantly
different (p<0.05).

in Fig. 3B, treatment with TF3 maximally increased the
caspase‑3/7 enzymatic activity to 2.19- and 1.20-fold of that
in controls for A2780/CP70 and IOSE-364 cells, respectively
(p<0.05), indicating that TF3 had more potential to induce
apoptosis in the ovarian cancer cells than the normal ovarian
cells in this study.
TF3 induces G2 cell cycle arrest in A2780/CP70 cells. To
determine whether the growth inhibitory effect of TF3 is
caused by specific perturbation of cell cycle-related events, cell
cycle phase distribution of cells treated with TF3 (0-20 µM)
for 24 h was analyzed by flow cytometry after propidium
iodide staining. As shown in Fig. 4 and Table I, treatment
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Figure 3. TF3 induces apoptosis in A2780/CP70 and IOSE‑364 cells. (A) Flow cytometry of TF3 treated A2780/CP70 and IOSE‑364 cells using a doublestaining method with FITC-conjugated Annexin V and PI. The upper left and low left quadrant indicate the percentage of dead and live cells, respectively, and
the upper right and low right quadrants indicate the percentage of late and early apoptotic cells, respectively. (B) Caspase-3/7 activity levels with TF3-treatment
for 24 h. The caspase-3/7 activity of the control cells after treatment was arbitrarily expressed as 100%. Data represent means ± SD of three independent
experiments. Significant differences among the treatments are indicated by different letters (p<0.05).

Figure 4. TF3 induces cell cycle arrest in A2780/CP70 and IOSE-364 cells. Cells were treated with various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h,
fixed in 70% ethanol, and stained with propidium iodide. DNA contents were determined by flow cytometry.
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Figure 5. Effect of TF3 on the intrinsic apoptotic pathway in A2780/CP70
cells. Protein lysates were prepared from A2780/CP70 cells after treatment
with various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. Puma, Bax,
Bad, Bcl-xL and caspase-9 protein levels were analyzed by western blotting.
The quantification histograms are shown with error bars. Data represent
means ± SD from three independent experiments. Significant differences
among the treatments are indicated by different letters (p<0.05).

Figure 6. Effect of TF3 on the extrinsic apoptotic pathway in A2780/CP70
cells. Protein lysates were prepared from A2780/CP70 cells after treatment
with various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. DR5,
FADD, procaspase-8 and cleaved caspase-8 protein levels were analyzed by
western blotting. The quantification histograms are shown with error bars.
Data represent means ± SD from three independent experiments. Significant
differences among different treatments are indicated by different letters
(p<0.05).

of A2780/CP70 and IOSE‑364 cells with TF3 resulted in a
significant increase in the proportion of cells at the G2 phase
in a concentration-dependent manner (p<0.05). The G2 phase
percentage of the A2780/CP70 cells increased by 21.78%,
while that of IOSE‑364 cells increased by 6.68% after 20 µM
TF3 treatment for 24 h. These results suggested that TF3
had more potent capability to induce G2 cell cycle arrest for
ovarian cancer cells than the ovarian normal cells.

Bcl-2 family proteins (Puma, Bax and Bad), anti-apoptotic
Bcl-2 family protein Bcl-xL, and caspase-9 by western blotting. Fig. 5 shows TF3 significantly increased the protein levels
of Bax, Bad and cleaved caspase-9, reduced protein expressions of Bcl-xL and procaspase-9 (p<0.05), and had no effect
on Puma protein expression (p>0.05). These results suggested
that TF3 induced apoptosis in A2780/CP70 cells through the
intrinsic apoptotic pathway.

Effect of TF3 on the intrinsic apoptotic pathway in A2780/
CP70 cells. Apoptosis can be initiated via two canonical pathways: the intrinsic or mitochondrial pathway, and the extrinsic
or receptor-mediated pathway. To clarify whether the intrinsic
pathway is involved in TF3-induced apoptosis of A2780/CP70
cells, we examined the protein expression of pro-apoptotic

Effect of TF3 on the extrinsic apoptotic pathway in A2780/
CP70 cells. Next, we investigated whether TF3 could activate
the extrinsic apoptotic pathway in A2780/CP70 cells. As
shown in Fig. 6, TF3 significantly increased protein expression of DR5, FADD and cleaved caspase-8, and decreased the
protein level of procaspase-8 (p<0.05). These results indicated
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Figure 7. Effect of TF3 on cell cycle G2-related proteins in A2780/CP70 cells.
Protein lysates were prepared from A2780/CP70 cells after treatment with
various concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. p21, cyclin B1,
phospho-cdc2 and total-cdc2 protein expression levels were analyzed by
western blotting. The quantification histograms are shown with error bars.
Data represent means ± SD from three independent experiments. Significant
differences among the treatments are indicated by different letters (p<0.05).

that the extrinsic pathway was involved in TF3-induced apoptosis of A2780/CP70 cells.
Effect of TF3 on cell cycle G2-related proteins. To investigate
the underlying mechanism of the G2 arrest induced by TF3 in
A2780/CP70 cells, we evaluated the effect of TF3 on cell cycle
regulatory proteins that play important roles in G2 cell cycle
progression by western blot analysis. As shown in Fig. 7, TF3
could effectively suppress cyclin B1 expression (p<0.05), but
had no effect on the protein levels of p21, phospho-cdc2 (Tyr15)
or total-cdc2 (p>0.05). These results implied that the downregulation of cyclin B1 protein expression may be responsible
for the G2 growth arrest induced by TF3 in A2780/CP70 cells.
Role of p53 in TF3-induced apoptosis and cell cycle arrest.
The p53 signaling pathway is a well-known crucial modulator
of cell survival, apoptosis and cell cycle arrest (18). To clarify

Figure 8. Role of p53 in TF3-induced apoptosis and G2 cell cycle arrest of
A2780/CP70 cells. The quantification histograms are shown with error bars.
Data represent means ± SD from three independent experiments. (A) The
effects of TF3 on the protein expression of p53 determined by western blotting. Significant differences among the treatments are indicated by different
letters (p<0.05). (B) The effects of p53 siRNA (50 nM) on the protein expression of procaspase-8, procaspase-9 and cyclin B1 determined by western
blotting. *p<0.05, **p<0.01, compared with respective controls.

the role of p53 in TF3-induced apoptosis and cell cycle arrest,
p53 protein expression was determined by western blotting.
Fig. 8A shows that TF3 upregulated the protein expression of
p53 in A2780/CP70 cells (p<0.05). To further analyze the role
of p53 in TF3-induced cell death, p53 was selectively knocked
down by siRNA approach. Fig. 8B shows that p53 protein level
was obviously inhibited after treatment with 50 nM p53 siRNA
(p<0.01). This p53 depletion led to abrogation of TF3-induced
decrease in cyclin B1, procaspase-8 and procaspase-9 protein
expression (p<0.05). These results suggested that TF3 induced

INTERNATIONAL JOURNAL OF ONCOLOGY 48: 2657-2665, 2016

Figure 9. Effect of TF3 on Akt/MDM2 pathway in A2780/CP70 cells. Protein
lysates were prepared from A2780/CP70 cells after treatment with various
concentrations (0, 5, 10 and 20 µM) of TF3 for 24 h. phospho-Akt, total-Akt
and MDM2 protein expression levels were analyzed by western blotting. The
quantification histograms are shown with error bars. Data represent means
± SD from three independent experiments. Significant differences among the
treatments are indicated by different letters (p<0.05).

apoptosis and G2 cell cycle arrest at least partly through p53
in A2780/CP70 cells.
Regulation of phospho-Akt, total-Akt and MDM2 protein
expression by TF3. Akt is considered as a determinant of
cisplatin resistance in ovarian cancer cells (19). Murine double
minute 2 (MDM2) is an important negative regulator of p53
that directly inhibits p53 transcriptional activity and enhances
p53 degradation via the ubiquitin-proteasome pathway (20).
Therefore, we tested the effects of TF3 on the expression of Akt
and its downstream effector MDM2. As shown in Fig. 9, TF3
significantly decreased the phosphorylation of Akt without
the influence on total Akt protein expression, and reduced the
protein level of MDM2 (p<0.05).
Discussion
Although cisplatin-centered chemotherapy is the first-line
anticancer agent for human ovarian cancer, chemoresistance
and adverse side effects remain major hurdles to successful
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treatment (21). Natural products have recently received
renewed focus as a rich repository for drug discovery (22).
(-)-Epigallocatechin-3-gallate (EGCG), the most abundant
catechin monomer in green tea, was reported to potently
suppress ovarian cancer cell growth alone, and potentiate the
inhibiting effect of sulforaphane on paclitaxel-resistant ovarian
cancer cell lines (23). TF3 is the oxidation product of (-)-epicatechin gallate (ECG) and EGCG, and has been found to possess
stronger antioxidant and anti-inflammation activities compared
with EGCG (8,24). These findings stimulated our interest in
investigating the effect of TF3 on the ovarian cancer cells.
In this study, we found that the IC50 value of TF3 for
A2780/CP70 was 23.81 µM, which was around half of the IC50
(59.58 µM) for TF3 in the IOSE‑364 cells (Fig. 2), and that
(47.9 µM) for cisplatin in the A2780/CP70 cells as reported
in our previous study (25). Flow cytometry analysis and
caspase‑3/7 activity assay suggested that TF3 had more potential to induce apoptosis and G2 cell cycle arrest of A2780/CP70
cells with respect to IOSE‑364 cells (Figs. 3 and 4), which
provided a possible explanation for the preferential cell growth
inhibitory effect by TF3.
A decreased susceptibility of ovarian cancer to apoptosis
was strongly associated with drug resistance (26). Agents that
target the apoptotic pathway have been shown to sensitize
tumor cells to chemotherapy and radiotherapy (27). Apoptosis
can be initiated via the intrinsic and extrinsic pathways, which
both ultimately activate the same effector caspases (3, 6 and 7)
and apoptosis effector molecules. The intrinsic apoptosis
pathway is triggered by intracellular signals such as cellular
and DNA damage. Key events are the depolarization of the
mitochondrial membrane potential and the release of mitochondrial factors such as cytochrome c into the cytosol, which
results in activation of initiator caspase-9. Mitochondrial activation is critically controlled by the family of Bcl-2 proteins,
which consists of pro- and anti-apoptotic members (28). The
extrinsic pathway implicates the activation of death receptors
at the plasma membrane level. Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) interacts with the death
domain-containing receptors DR4/DR5 or Fas, resulting
in the recruitment of Fas-associated death domain (FADD),
procaspase-8, and procaspase-10 to form the death-inducing
signaling complex (DISC) (29). It was reported that the
differential induction of apoptosis in cancer versus normal
cells involves direct targeting of mitochondria associated
with alterations in the balance of Bcl-2 proteins (30). Another
explanation is that normal cells are resistant to the tumor
necrosis factor related apoptosis-inducing ligand (TRAIL)
due to the high TRID levels, whereas tumor lines carrying
TRAIL-receptors in most cases can not be protected (31).
Theaflavins have been reported to target the Fas/caspase-8
pathway to induce apoptosis in human breast cancer cells, and
influence Bcl-2 protein expression in an experimental lung
cancer mouse model (32,33). In this study, treatment with TF3
significantly regulated the protein expression of Bcl-2 family
proteins (Bax, Bad and Bcl-xL), DR5, FADD, caspase-8 and
-9 (Figs. 5 and 6), indicating that TF3 induced apoptosis
through both intrinsic and extrinsic pathways in A2780/CP70
cells. Induction of apoptosis might account for the preferential
inhibitory effect of TF3 on ovarian cancer A2780/CP70 cells
vs. normal ovarian IOSE‑364 cells.
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Cancer is a disease of inappropriate cell proliferation. It
was revealed that many cancer cells have defective G1 checkpoint mechanisms, and depend on G2 checkpoint during cell
replication far more than normal cells. These insights have
given birth to the idea of cell cycle G2 checkpoint abrogation
as a cancer cell specific therapy (34). Our cell cycle analysis
showed that TF3 induced more prominent G2 arrest in A2780/
CP70 cells than in IOSE‑364 cells (Fig. 4 and Table I),
suggesting that in addition to apoptosis, G2 cell cycle arrest
was another factor that contributed to the preferential cell
growth inhibition. Transition through G1 to S phase is regulated by the cyclin A-Cdk2 and cyclin E-Cdk2 complexes.
Inactivation of cyclin B-Cdc2 leads to the G2/M arrest (35).
The p21 protein is a potent cyclin-dependent kinase inhibitor,
and functions as a regulator of cell cycle progression at G1
and G2 phase (36). A previous study showed that theaflavins
induced G2/M arrest by modulating expression of p21, cdc25C
and cyclin B in human prostate carcinoma PC-3 cell (37).
However, our data showed that TF3 could not influence the
p21, phospho-cdc2 (Tyr15) and total-cdc2 protein levels, but
significantly decreased cyclin B1 expression (Fig. 7), indicating cyclin B1 played an important role in the TF3-induced
G2 arrest of A2780/CP70 cells.
The tumor suppressor protein, p53, transcriptionally
activates genes that control cell cycle arrest, apoptosis, and
other cellular processes that help to prevent tumor development. p53 stimulates apoptosis by a wide network of signals
including the extrinsic pathway such as Killer/DR5 and
Fas/APO-1, and intrinsic pathway including proteins Bax,
Puma and Noxa (38). In addition, p53 contributes to cell
cycle arrest, blocking the cell at the G1, S or G2/M phase
by inducing expression of p21 and the consequent inhibition
of cyclin D/Cdks, decreasing cyclin B1 transcription and
synthesis, or inactivates Cdc2 through Cdc25C (39). It is of
particular interest in ovarian cancer in view of the association
of platinum sensitivity and p53 pathway alterations. However,
wild-type p53 status is often, but not always, associated with
cisplatin sensitivity (40).
It is known that A2780/CP70 cell line has a wild-type
p53 gene sequence (41). In this study, we found that TF3
significantly increased the p53 protein expression (Fig. 8A).
Furthermore, transfection with the p53 siRNA tended to
attenuate the reduction of procaspase-8, 9 and cyclin B1
protein expression induced by TF3 (Fig. 8). These results
suggested that p53 played an important role in TF3 induced
apoptosis and G2 cell cycle arrest of A2780/CP70 cells, which
was consistent with the previous reports that p53 promoted
theaflavin-induced apoptosis in human breast and prostate
cancer cells through mitochondrial death cascade (42,43), and
prevented G2/M transition by decreasing intracellular levels of
cyclin B1 protein in ovarian cancer Ts-SKOV3 cells (44).
Akt is a serine/threonine kinase that plays a critical role
in the malignant transformation of human tumors and their
subsequent growth, proliferation, and metastasis. Targeted
inhibition of the Akt pathway is a promising strategy for cancer
therapy and can also be useful for overcoming chemotherapy
resistance (45). The functional link between Akt-mediated
chemoresistance and p53 has been found. It was reported that
Akt could induce an MDM2-dependent downregulation of
p53, and suppression of Akt sensitized chemoresistant cells to

cisplatin in a p53-dependent manner (46). Our data showed
that TF3 treatment significantly decreased the phosphorylation of Akt and MDM2 protein level, indicating that TF3
might upregulate p53 expression through inactivation of Akt
and MDM2 in A2780/CP70 cells. Further in vivo studies in
animal models and human patients are necessary to ascertain
the anticancer effect of theaflavins against ovarian cancer.
In conclusion, this study demonstrated that TF3 had a
potent and preferential cell growth inhibitory effect on the
cisplatin-resistant ovarian cancer cell line A2780/CP70 with
respect to normal cell line IOSE‑364 via apoptosis and G2 cell
cycle arrest. TF3 induced apoptosis through both the intrinsic
and extrinsic pathways, and caused G2 cell cycle arrest via
cyclin B1 in A2780/CP70 cells. These activities were at least
partly mediated by p53 upregulation dependent of Akt and
MDM2. Based on these results, TF3 would be a promising
natural compound for prevention and treatment of platinumresistant ovarian cancer.
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